vs
Pacira BioSciences, Inc.（PCRX）与Ranger Energy Services, Inc.（RNGR）财务数据对比。点击上方公司名可切换其他公司
Pacira BioSciences, Inc.的季度营收约是Ranger Energy Services, Inc.的1.2倍（$177.4M vs $142.2M），Ranger Energy Services, Inc.净利率更高（2.3% vs 1.6%，领先0.6%），Pacira BioSciences, Inc.同比增速更快（5.0% vs -0.6%），过去两年Ranger Energy Services, Inc.的营收复合增速更高（1.9% vs -0.2%）
Pacira BioSciences是一家专科制药企业，专注于非阿片类疼痛管理药物的研发与商业化，核心产品线面向术后镇痛场景，服务以美国为主的医院、门诊手术中心等医疗服务机构，同时推进部分国际市场的拓展工作。
Ranger Energy Services是北美领先的陆上油田服务提供商，为上游油气运营商提供完井、修井、钻机作业及产能优化等全套解决方案，业务主要覆盖美国本土的页岩和致密资源开采作业区。
PCRX vs RNGR — 直观对比
营收规模更大
PCRX
是对方的1.2倍
$142.2M
营收增速更快
PCRX
高出5.6%
-0.6%
净利率更高
RNGR
高出0.6%
1.6%
两年增速更快
RNGR
近两年复合增速
-0.2%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $177.4M | $142.2M |
| 净利润 | $2.9M | $3.2M |
| 毛利率 | — | — |
| 营业利润率 | 3.9% | 2.3% |
| 净利率 | 1.6% | 2.3% |
| 营收同比 | 5.0% | -0.6% |
| 净利润同比 | — | -44.8% |
| 每股收益（稀释后） | $0.07 | $0.14 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PCRXRNGR
| Q1 26 | $177.4M | — | ||
| Q4 25 | $196.9M | $142.2M | ||
| Q3 25 | $179.5M | $128.9M | ||
| Q2 25 | $181.1M | $140.6M | ||
| Q1 25 | $168.9M | $135.2M | ||
| Q4 24 | $187.3M | $143.1M | ||
| Q3 24 | $168.6M | $153.0M | ||
| Q2 24 | $178.0M | $138.1M |
净利润PCRXRNGR
| Q1 26 | $2.9M | — | ||
| Q4 25 | — | $3.2M | ||
| Q3 25 | $5.4M | $1.2M | ||
| Q2 25 | $-4.8M | $7.3M | ||
| Q1 25 | $4.8M | $600.0K | ||
| Q4 24 | — | $5.8M | ||
| Q3 24 | $-143.5M | $8.7M | ||
| Q2 24 | $18.9M | $4.7M |
毛利率PCRXRNGR
| Q1 26 | — | — | ||
| Q4 25 | 79.5% | — | ||
| Q3 25 | 80.9% | — | ||
| Q2 25 | 77.4% | — | ||
| Q1 25 | 79.7% | — | ||
| Q4 24 | 78.7% | — | ||
| Q3 24 | 76.9% | — | ||
| Q2 24 | 75.1% | — |
营业利润率PCRXRNGR
| Q1 26 | 3.9% | — | ||
| Q4 25 | 1.2% | 2.3% | ||
| Q3 25 | 3.5% | 2.0% | ||
| Q2 25 | 4.7% | 6.1% | ||
| Q1 25 | 1.2% | 0.7% | ||
| Q4 24 | 13.2% | 6.2% | ||
| Q3 24 | -82.8% | 8.4% | ||
| Q2 24 | 15.9% | 5.3% |
净利率PCRXRNGR
| Q1 26 | 1.6% | — | ||
| Q4 25 | — | 2.3% | ||
| Q3 25 | 3.0% | 0.9% | ||
| Q2 25 | -2.7% | 5.2% | ||
| Q1 25 | 2.8% | 0.4% | ||
| Q4 24 | — | 4.1% | ||
| Q3 24 | -85.1% | 5.7% | ||
| Q2 24 | 10.6% | 3.4% |
每股收益（稀释后）PCRXRNGR
| Q1 26 | $0.07 | — | ||
| Q4 25 | $0.05 | $0.14 | ||
| Q3 25 | $0.12 | $0.05 | ||
| Q2 25 | $-0.11 | $0.32 | ||
| Q1 25 | $0.10 | $0.03 | ||
| Q4 24 | $0.38 | $0.24 | ||
| Q3 24 | $-3.11 | $0.39 | ||
| Q2 24 | $0.39 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $144.3M | $10.3M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $653.9M | $300.1M |
| 总资产 | $1.2B | $419.3M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PCRXRNGR
| Q1 26 | $144.3M | — | ||
| Q4 25 | $238.4M | $10.3M | ||
| Q3 25 | $246.3M | $45.2M | ||
| Q2 25 | $445.9M | $48.9M | ||
| Q1 25 | $493.6M | $40.3M | ||
| Q4 24 | $484.6M | $40.9M | ||
| Q3 24 | $453.8M | $14.8M | ||
| Q2 24 | $404.2M | $8.7M |
总债务PCRXRNGR
| Q1 26 | — | — | ||
| Q4 25 | $372.2M | — | ||
| Q3 25 | $376.7M | — | ||
| Q2 25 | $580.5M | — | ||
| Q1 25 | $583.4M | — | ||
| Q4 24 | $585.3M | $0 | ||
| Q3 24 | — | $0 | ||
| Q2 24 | — | $0 |
股东权益PCRXRNGR
| Q1 26 | $653.9M | — | ||
| Q4 25 | $693.1M | $300.1M | ||
| Q3 25 | $727.2M | $270.0M | ||
| Q2 25 | $757.8M | $276.9M | ||
| Q1 25 | $798.5M | $272.6M | ||
| Q4 24 | $778.3M | $273.8M | ||
| Q3 24 | $749.6M | $267.6M | ||
| Q2 24 | $879.3M | $260.5M |
总资产PCRXRNGR
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.3B | $419.3M | ||
| Q3 25 | $1.3B | $372.8M | ||
| Q2 25 | $1.5B | $381.7M | ||
| Q1 25 | $1.6B | $376.5M | ||
| Q4 24 | $1.6B | $381.6M | ||
| Q3 24 | $1.5B | $373.9M | ||
| Q2 24 | $1.6B | $359.6M |
负债/权益比PCRXRNGR
| Q1 26 | — | — | ||
| Q4 25 | 0.54× | — | ||
| Q3 25 | 0.52× | — | ||
| Q2 25 | 0.77× | — | ||
| Q1 25 | 0.73× | — | ||
| Q4 24 | 0.75× | 0.00× | ||
| Q3 24 | — | 0.00× | ||
| Q2 24 | — | 0.00× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $24.1M |
| 自由现金流经营现金流 - 资本支出 | — | $17.1M |
| 自由现金流率自由现金流/营收 | — | 12.0% |
| 资本支出强度资本支出/营收 | — | 4.9% |
| 现金转化率经营现金流/净利润 | — | 7.53× |
| 过去12个月自由现金流最近4个季度 | — | $42.9M |
8季度趋势，按日历期对齐
经营现金流PCRXRNGR
| Q1 26 | — | — | ||
| Q4 25 | $43.7M | $24.1M | ||
| Q3 25 | $60.8M | $13.6M | ||
| Q2 25 | $12.0M | $20.7M | ||
| Q1 25 | $35.5M | $10.6M | ||
| Q4 24 | $33.1M | $32.7M | ||
| Q3 24 | $53.9M | $17.7M | ||
| Q2 24 | $53.2M | $22.1M |
自由现金流PCRXRNGR
| Q1 26 | — | — | ||
| Q4 25 | $43.5M | $17.1M | ||
| Q3 25 | $57.0M | $8.0M | ||
| Q2 25 | $9.3M | $14.4M | ||
| Q1 25 | $26.9M | $3.4M | ||
| Q4 24 | $31.0M | $27.3M | ||
| Q3 24 | $49.8M | $10.8M | ||
| Q2 24 | $51.6M | $6.8M |
自由现金流率PCRXRNGR
| Q1 26 | — | — | ||
| Q4 25 | 22.1% | 12.0% | ||
| Q3 25 | 31.7% | 6.2% | ||
| Q2 25 | 5.1% | 10.2% | ||
| Q1 25 | 15.9% | 2.5% | ||
| Q4 24 | 16.6% | 19.1% | ||
| Q3 24 | 29.6% | 7.1% | ||
| Q2 24 | 29.0% | 4.9% |
资本支出强度PCRXRNGR
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 4.9% | ||
| Q3 25 | 2.2% | 4.3% | ||
| Q2 25 | 1.5% | 4.5% | ||
| Q1 25 | 5.1% | 5.3% | ||
| Q4 24 | 1.1% | 3.8% | ||
| Q3 24 | 2.4% | 4.5% | ||
| Q2 24 | 0.9% | 11.1% |
现金转化率PCRXRNGR
| Q1 26 | — | — | ||
| Q4 25 | — | 7.53× | ||
| Q3 25 | 11.20× | 11.33× | ||
| Q2 25 | — | 2.84× | ||
| Q1 25 | 7.37× | 17.67× | ||
| Q4 24 | — | 5.64× | ||
| Q3 24 | — | 2.03× | ||
| Q2 24 | 2.82× | 4.70× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
RNGR
| High Specification Rigs | $92.3M | 65% |
| Processing Solutions And Ancillary Services | $37.5M | 26% |
| Wireline Services | $12.4M | 9% |
